Informações de AstraZeneca PLC | Histórico, dados financeiros e desempenho de mercado

Mais detalhes de AstraZeneca PLC Empresa

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

Informações da empresa

Código da empresaAZN

Nome da EmpresaAstraZeneca PLC

Data de listagemSep 21, 2007

Fundado em1992

CEOMr. Marc Dunoyer

Número de funcionários94300

Tipo de títulosOrdinary Share

Fim do ano fiscalSep 21

Endereço1 Francis Crick Avenue

CidadeCAMBRIDGE

Bolsa de valoresLondon Stock Exchange

PaísUnited Kingdom

Código postalCB2 0AA

Telefone442073045000

Sitehttps://www.astrazeneca.com/

Código da empresaAZN

Data de listagemSep 21, 2007

Fundado em1992

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Susan Galbraith

Executive Vice President - Oncology and Research and Development

--

Mr. Marc Dunoyer

Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca

--

Mr. David (Dave) Fredrickson

Executive Vice President - Oncology Business Unit

--

Mr. Pascal Soriot

Chief Executive Officer, Executive Director

--

Mr. Philip Broadley

Senior Non-Executive Independent Director

--

Dr. Ruud Dobber, Ph.D.

Executive Vice President - BioPharmaceuticals Business Unit

--

Ms. Diana Layfield

Non-Executive Independent Director

--

Mr. Rene Haas

Non-Executive Director

--

Mr. Michel Demare

Non-Executive Independent Chairman of the Board

--

Ms. Aradhana Sarin, M.D.

Chief Financial Officer, Executive Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Susan Galbraith

Executive Vice President - Oncology and Research and Development

--

Mr. Marc Dunoyer

Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca

--

Mr. David (Dave) Fredrickson

Executive Vice President - Oncology Business Unit

--

Mr. Pascal Soriot

Chief Executive Officer, Executive Director

--

Mr. Philip Broadley

Senior Non-Executive Independent Director

--

Dr. Ruud Dobber, Ph.D.

Executive Vice President - BioPharmaceuticals Business Unit

--

Detalhamento da receita

Moeda: USDTempo de atualização: dom, 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Farxiga

7.66B

15.03%

Tagrisso

6.58B

12.92%

Imfinzi

4.72B

9.26%

Ultomiris

3.92B

7.70%

Calquenc

3.13B

6.14%

Other

24.93B

48.95%

Por RegiãoUSD

Nome

Receita

Proporção

United States

21.81B

42.81%

China

6.42B

12.60%

United Kingdom

4.74B

9.31%

Other European Countries

3.66B

7.19%

Japan

3.45B

6.78%

Other

10.86B

21.32%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Farxiga

7.66B

15.03%

Tagrisso

6.58B

12.92%

Imfinzi

4.72B

9.26%

Ultomiris

3.92B

7.70%

Calquenc

3.13B

6.14%

Other

24.93B

48.95%

Acionista

Tempo de atualização: sex, 21 de fev

Estatísticas dos acionistas

Tipo

Estatísticas dos acionistas

Acionista

Proporção

PRIMECAP Management Company

1.32%

Capital International Investors

1.21%

Wellington Management Company, LLP

1.19%

T. Rowe Price Associates, Inc.

1.09%

T. Rowe Price International Ltd

0.86%

Other

94.33%

Estatísticas dos acionistas

Acionista

Proporção

PRIMECAP Management Company

1.32%

Capital International Investors

1.21%

Wellington Management Company, LLP

1.19%

T. Rowe Price Associates, Inc.

1.09%

T. Rowe Price International Ltd

0.86%

Other

94.33%

Tipo

Acionista

Proporção

Investment Advisor

9.45%

Investment Advisor/Hedge Fund

5.99%

Hedge Fund

0.96%

Research Firm

0.88%

Bank and Trust

0.15%

Pension Fund

0.04%

Venture Capital

0.02%

Family Office

0.02%

Family Office

0.02%

Other

82.47%

Participação acionária institucional

Tempo de atualização: dom, 19 de jan

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q1

1957

546.41M

17.61%

+3.36M

2024Q4

1985

546.17M

17.61%

+11.21M

2024Q3

1920

519.95M

16.76%

-17.37M

2024Q2

1910

530.80M

17.12%

-10.51M

2024Q1

1865

523.00M

16.86%

-21.20M

2023Q4

1838

520.78M

16.79%

-27.28M

2023Q3

1815

530.17M

17.10%

-14.80M

2023Q2

1812

525.36M

16.94%

-28.74M

2023Q1

1803

534.31M

17.23%

-35.06M

2022Q4

1806

550.27M

17.75%

-33.14M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

PRIMECAP Management Company

41.02M

1.32%

-960.52K

-2.29%

Dec 31, 2024

Capital International Investors

37.51M

1.21%

+686.01K

+1.86%

Dec 31, 2024

Wellington Management Company, LLP

37.04M

1.19%

-208.20K

-0.56%

Dec 31, 2024

T. Rowe Price Associates, Inc.

33.74M

1.09%

-3.07M

-8.34%

Dec 31, 2024

T. Rowe Price International Ltd

26.61M

0.86%

+530.22K

+2.03%

Dec 31, 2024

Fidelity Management & Research Company LLC

18.15M

0.59%

-1.10M

-5.70%

Dec 31, 2024

Managed Account Advisors LLC

16.43M

0.53%

-1.13M

-6.44%

Dec 31, 2024

Jennison Associates LLC

15.43M

0.5%

+466.42K

+3.12%

Dec 31, 2024

Sanders Capital, LLC

15.19M

0.49%

+212.30K

+1.42%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

12.04M

0.39%

+161.77K

+1.36%

Feb 28, 2025

Ver Mais

ETFs Relacionados

Tempo de atualização: sáb, 5 de abr

Nome

Proporção

First Trust WCM International Equity ETF

6.02%

Amplify Weight Loss Drug & Treatment ETF

5.95%

Parnassus Value Select ETF

5.6%

VanEck Pharmaceutical ETF

5.09%

Roundhill GLP-1 & Weight Loss ETF

4.88%

ProShares Ultra Nasdaq Biotechnology

4.27%

Invesco Nasdaq Biotechnology ETF

4.25%

Invesco QQQ Low Volatility ETF

4.19%

PGIM Jennison Focused Value ETF

3.39%

Global X Aging Population ETF

2.87%

Ver Mais

First Trust WCM International Equity ETF

Proporção6.02%

Amplify Weight Loss Drug & Treatment ETF

Proporção5.95%

Parnassus Value Select ETF

Proporção5.6%

VanEck Pharmaceutical ETF

Proporção5.09%

Roundhill GLP-1 & Weight Loss ETF

Proporção4.88%

ProShares Ultra Nasdaq Biotechnology

Proporção4.27%

Invesco Nasdaq Biotechnology ETF

Proporção4.25%

Invesco QQQ Low Volatility ETF

Proporção4.19%

PGIM Jennison Focused Value ETF

Proporção3.39%

Global X Aging Population ETF

Proporção2.87%

Dividendo

Um total de 20.90B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Feb 06, 2025

AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025

Feb 21, 2025

Mar 24, 2025

Feb 21, 2025

Jul 25, 2024

AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024

Aug 09, 2024

Sep 09, 2024

Aug 09, 2024

Feb 08, 2024

AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024

Feb 23, 2024

Mar 25, 2024

Feb 22, 2024

Jul 28, 2023

AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023

Aug 11, 2023

Sep 11, 2023

Aug 10, 2023

Feb 10, 2023

AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023

Feb 24, 2023

Mar 27, 2023

Feb 23, 2023

Aug 01, 2022

AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022

Aug 12, 2022

Sep 12, 2022

Aug 11, 2022

Feb 10, 2022

AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022

Feb 25, 2022

Mar 28, 2022

Feb 24, 2022

Aug 02, 2021

AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021

Aug 13, 2021

Sep 13, 2021

Aug 12, 2021

Feb 11, 2021

AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021

Feb 26, 2021

Mar 29, 2021

Feb 25, 2021

Jul 30, 2020

AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 14, 2020 going ex on Aug 13, 2020

Aug 14, 2020

Sep 14, 2020

Aug 13, 2020

Ver Mais

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

AstraZeneca PLC

69.570USD

AstraZeneca PLC

69.570

Visão Geral

Empresa